Browse Articles
Discover research articles across all indexed journals
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.
140 Background: In the phase II EXTEND iADT omPC basket, MDT+iADT improved progression-free survival (PFS) vs iADT. Here we present the primary results of the EXTEND cADT omPC basket. We further report a pre-specified combined analysis with updated results from the iADT basket and examine the effects of MDT on immunity. Methods: Patients with 1 to 5 omPC metastases were randomized 1:1 to MDT+cADT vs cADT (NCT03599765). MDT consisted of definitive local therapy. cADT consisted of ADT +/- second-generation anti-androgens. The primary endpoint was per-protocol PFS, defined by biochemical criteria (Prostate Cancer Working Group 3), radiologic measures (RECIST v1.1), clinical progression, or death. 87 patients were needed to show superiority at a one-sided P of 0.10 by log-rank test. CDR3 regions in rearranged T cell receptor (TCR) β-chains from pre- and post-enrollment peripheral blood were sequenced with immunoSEQ (Adaptive Biotech). TCR repertoire modulation was defined as having TCR expansion plus contraction using a false-discovery-corrected betabinomial model. TCR sequencing from the ORIOLE trial (NCT02680587) was assessed for external validation. Results: From 2018 to 2022, 87 randomized patients were treated per protocol (MDT+cADT: 45; cADT: 42). 39% had castrate resistant omPC. MDT was definitive radiotherapy in all cases. With median follow-up of 31 mo, median PFS was 47 mo after MDT+cADT vs 22 mo after cADT (HR 0.50; 95% CI 0.23 to 1.08; one-sided P = 0.036). In the combined analysis (N=174) with median follow-up of 42 mo, MDT+ADT improved PFS (HR 0.45; 95% CI 0.30 to 0.69; P < 0.001), radiologic PFS (HR 0.63; 95% CI 0.40 to 0.97; P = 0.038), and castration-resistance free-survival (HR 0.40; 95% CI 0.19 to 0.82; P = 0.013). MDT+ADT had higher odds of TCR repertoire modulation vs ADT (55% vs 15%, P < 0.001). This finding was validated in the ORIOLE trial (MDT: 57% vs observation: 19%, P = 0.03). Among the subset of patients with extreme responses, random forest modeling of 37 clinical/immune variables identified TCR repertoire modulation as the variable with highest importance; further, MDT+ADT induced TCR repertoire modulation in all patients with favorable responses (i.e. PFS > 4 years) and none with unfavorable responses (i.e. PFS < 1 year). Among all patients randomized to MDT+ADT, TCR repertoire modulation was associated with longer PFS (HR 0.21; 95% CI 0.06 to 0.76; P = 0.02). Conclusions: MDT+cADT met the PFS primary endpoint of the phase II EXTEND trial, warranting phase III testing. From the combined analysis, MDT+ADT may also improve longer term outcomes including radiologic PFS and castration-resistance-free survival. Improved outcomes may result from MDT-induced immunomodulation, with implications for future trial design. Clinical trial information: NCT03599765 .
Characterizing pre-discharge interventions to reduce length of stay for older adults: A scoping review
Background Hospital pre-discharge interventions are becoming one of the leading strategies to promote early discharge. For older adult patients, it remains unclear what these interventions are and how they affect discharge outcomes. Objective This scoping review categorizes pre-discharge interventions promoting early acute care hospital discharging or total hospital length of stay reductions among older adults, synthesizes contextual factors (e.g., cost, staffing) driving implementation, and assesses the perceived intervention’s impact. Design The review followed the five states of the Arksey and O’Malley framework and the PRISMA-ScR extension. The PubMed, Embase, and Scopus databases were searched from 1983 to 2020 for pre-discharge interventions designed or adapted to discharge older adults earlier in their stay from acute care hospitals. Potentially relevant articles were screened against eligibility criteria. Findings were extracted and collated in data charting forms followed by brief thematic analyses. Results The search yielded 5,455 articles of which 91 articles were included. Eight pre-discharge intervention categories were identified: clinical management, diagnostic/risk assessment tools, staffing enhancements, drug administration, length of stay protocols, nutrition planning, and communication improvements. Leading motivations for intervention implementation included the nationwide drive to reduce care costs and hospitals’ need to increase hospital profitability, improve quality of care, or optimize resource utilization. Discharge outcomes reported included hospitalization costs, readmission rates, mortality rates, resource utilization rates and costs, and length of stay. Mixed results were found regarding the effectiveness of early discharge interventions on discharge outcomes based on expressed author sentiment. Conclusions The drive for pre-discharge interventions that reduce older adult hospital stays and associated costs continues to stem primarily from economic and governmental policies. Follow-up studies may be required to emphasize patient perspectives and care trajectories to avoid unintentional costly and health-deteriorating consequences.
Two-mode light in optomechanical cavity with squeezed vacuum reservoir
Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: A comparative analysis with axitinib combined with standard-dose toripalimab.
532 Background: Oligometastatic renal cell carcinoma (RCC) involves limited metastases (1-5) and lies between localized and metastatic disease, with lower tumor burden. Studies suggest these patients may respond well to local or systemic therapies like targeted or immunotherapy. Combining renal tumor embolization with these therapies is emerging as a promising option. However, comparative data on embolization versus non-embolization treatments remain scarce. This study compares efficacy and adverse events of these treatments in oligometastatic RCC using propensity score matching. Methods: This study included oligometastatic clear cell RCC patients treated since March 2023, divided into two groups. The experimental group received renal tumor embolization, axitinib (5 mg twice daily), and reduced-dose toripalimab (160 mg every 3 weeks). The control group received standard axitinib and toripalimab (240 mg every 3 weeks). All patients had their first follow-up three months post-treatment to assess efficacy and adverse effects. Propensity score matching (PSM) was used to balance demographics, tumor characteristics, and treatment history. The primary outcomes were disease control rate (DCR) and partial response rate (PR), with secondary outcomes being grade 3-4 adverse events. Results: 58 patients were included, 29 in each group after matching. All covariates had SMD values < 0.1, indicating good baseline balance. The experimental group had a DCR of 100% and PR of 93.1%, compared to DCR of 69.8% and PR of 56.7% in the control group (P < 0.05). In 4 patients with renal vein tumor thrombus, tumor size reduced by over 50%, and thrombus control was effective. Grade 3-4 adverse events were lower in the experimental group (10.1% vs. 38.4%, P < 0.05), mainly hypertension, hand-foot syndrome, and liver dysfunction. Conclusions: Propensity score matching showed that renal tumor embolization combined with axitinib and reduced-dose toripalimab improved efficacy and reduced grade 3-4 adverse events in oligometastatic RCC patients. Larger randomized trials are needed to confirm these findings and explore personalized treatment strategies to improve long-term survival and quality of life.
Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours.
636 Background: Testicular germ cell tumours (GCT) are the most common malignancy in young men, mainly in their 30s. While multimodal treatment leads to excellent survival in younger patients (pts), its incidence is rising in men over 50, who often have comorbidities and higher risks of chemotherapy (ChT) toxicity. Limited data on outcomes in this group highlights the need for more research. Methods: We conducted a retrospective single centre study, analysing pts diagnosed with GCT aged 50 years or older between 2014 -2023. Results: 142 pts were analysed, median age of 57 years (range 50–83). Most pts had an ECOG performance status of 0 (59%), and 26% had ≥ three comorbidities. Seminoma (S) represented 70% of diagnoses, while non-seminoma (NS) 30%. Among NS, embryonal carcinoma (62%) and yolk sac tumor (55%) were the most common. Fifty-six percent had stage I, 42% were above stage I and 2% had an unknown stage. Among stage I pts, 64 had S and 16 had NS. 38 pts (48%) received adjuvant ChT: 29 S treated with carboplatin, 8 NS with BEP, and 1 with EP. Of those given adjuvant ChT, 9 relapsed (24%; 5 S, 4 NS), while 14 on active surveillance relapsed (33%; 12 S, 2 NS). Among metastatic pts, most were classified as IGCCCG good-risk (52%), followed by intermediate (23%) and poor-risk (16%). The most used protocols were EP (32%), BEP (25%), and Carboplatin (20%). Seven stage II seminoma pts received ChT-radiotherapy, with one relapse. The response to first-line treatment was favorable in 78% (n=50) of cases (CR/PR markers negative), while 16% (n=12) had an unfavorable response. The overall 5-year relapse-free survival rate for all pts was 63%, with rates of 70% for Stage I, 79% for Stage II, and 45% for Stage III. The 10-year overall survival rate was 70%, with 80% for Stage I and 59% for advanced stages. At analysis, 78% were alive and 75% in remission. Among those who died, 54% of deaths were due to GCT. Conclusions: Our study indicates that survival outcomes for pts with late-onset GCT are considerably less favourable compared to younger cohorts. The data suggests that a higher prevalence of comorbidities, treatment delays, and dose reductions, may contribute to these differences. Moreover, the number of pts relapsing after adjuvant ChT is particularly high and raises the question of whether older age GCT are biologically different. Further research on factors affecting treatment and survival is needed, as a tailored approach could address challenges and improve outcomes. Treatment delivery and toxicity. Category Data Baseline performance status 0: 58.5%1: 14.8%2: 3.5%3: 0.7%Unknown: 22.5% Total number of ChT cycles 1-2: 51.8%3-4: 36.1%>4: 12.1% ChT related toxicity Grade 3-4: 23.6%Hematological: 15.5%Non-hematological: 19.1%Unknown: 24.5% ChT delivery Delays: 11%Dose reduction: 11% Number of additional hospital admissions 0: 52.7%1: 12.7%2: 4.5%≥3: 5.4%Unknown: 24.7% Bleomycin delivery Given: 23.9%Omitted: 76.1%Incidence of pneumonitis: 11.5%
Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer.
380 Background: Node-positive prostate cancer (PCa) poses a unique treatment challenge since bowel radiation tolerance often limits the delivery of doses of 60-70Gy or more required to control gross nodal disease. IMPT is a novel therapeutic option which utilizes beam stopping properties to achieve dose sparing of normal organs with the ability to dose escalate (DE) with potentially greater safety. However, the safety of DE-IMPT in node positive PCa has not been well described. Methods: Data were reviewed for consecutive patients treated between 9/2018-4/2024 with DE-IMPT for radiographically detected node-positive PCa. Treatment to the prostate and seminal vesicles consisted of 78Gy/39fractions; elective nodal regions received 46-48.6Gy in 1.8-2Gy/fraction, as part of whole pelvis treatment, while positive nodes were DE to a mean equivalent dose at 2 Gy/fraction (EQD2) dose of 66Gy (54-77.1Gy) in 1.8-2.5Gy/fraction, based on respecting predefined surrounding organs at risk (OAR) tolerances. Acute toxicities were assessed at baseline, weekly during treatment, and up to 3 months post-IMPT using Common Terminology Criteria for Adverse Events (CTCAE version 5). Results: The study included 58 patients presenting with a mean of 3 positive nodes (1-12). Median follow up was 19.5 months (3-67 months). Median age was 73 years (49-86). Majority were high-risk: Gleason 8-10 (67.2%), T3a-b (50%), PSA > 20 (44.8%). Median prostate gland volume was 52cc (19-157). All pts received androgen deprivation therapy (ADT) with 97% completing at least 6 months; Androgen receptor pathway inhibitors were added in 26 pts (45%). Overall mean rectal V70, V60 and V50 were 6.7%, 11.2% and 16.5% while mean bladder V70, V60 and V50 were 12%, 17.3% and 24%, respectively. Mean small bowel dose to 1 cc volume D 1cc was 50.7Gy (45.6-57Gy), while mean Dmax point dose to 0.03cc was 52.2Gy (47.8-61.8). Worst acute Genitourinary (GU) toxicities Grade 0 and 1 were 1.7% and 12%, respectively. During treatment, 18/58 patients (31%) were started on Alpha-blockers for increased urinary frequency, retention and urgency, consistent with GU Grade 2 toxicity of which 7(39%) had discontinued medication by 3 months post-treatment. Before treatment, 32/58 (55.1%) were already on Alpha-blockers. There were no GU Grade ≥ 3 toxicities observed. Acute gastrointestinal (GI) Grade 0 and 1 were 43.1% and 53.5%, respectively. Grade 2 GI toxicities were observed in 2 (3.4%) patients consisting of diarrhea and proctitis. One patient (1.7%) developed transient Grade 3 enteritis. Conclusions: This contemporary series demonstrates that DE-IMPT is a safe treatment option for node-positive PCa with acceptable rates of acute grade 1 or 2 toxicity. Acute grade 3 toxicity was rare, occurring in only one patient in this cohort.
Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
494 Background: Immuno-oncology (IO)-based combination therapy with or without anti-vascular endothelial growth factor (VE) has become a standard of care for mnccRCC. However, real-world evidence on the effectiveness of contemporary therapies over traditional targeted therapies against mnccRCC is limited. Methods: Using the IMDC, patients with mnccRCC were classified into five subgroups based on 1L therapies: IOIO, IOVE, CABO, SUN/PAZ, and mammalian target of rapamycin (mTOR). Baseline patient characteristics, clinician assessment of objective response rates (ORRs) as per RECIST 1.1, and overall survival (OS) were compared across 1L therapies. Results: Of 1551 patients with mnccRCC, 180 (11.6%), 90 (5.8%), 45 (2.9%), 1039 (70.0%), and 197 (12.7%) received IOIO, IOVE, CABO, SUN/PAZ, and mTOR, respectively. The most common histology was papillary in 725 (46.7%), followed by unclassified in 287 (18.5%), chromophobe in 200 (12.9%), and translocation in 84 (5.4%), while sarcomatoid dedifferentiation was found in 236 (15.2%). The IMDC prognostic categories (favourable/intermediate/poor) differed significantly across 1L therapies: IOIO (6.7%/52.3%/40.9%), IOVE (26.9%/44.9%/28.2%), CABO (16.1%/53.2%/30.7%), SUN/PAZ (16.1%/53.2%/30.7%), and mTOR (9.6%/51.4%/39.0%). For the papillary subtype, ORRs and median OS were better in IOIO (26.1% and 31.9 months), IOVE (31.0% and 33.2 months), and CABO (36.8% and 30.7 months) than in SUN/PAZ (12.8% and 17.2 months) and mTOR (3.4% and 13.1 months), whereas for the unclassified subtype, CABO did not appear to be as effective as IOIO and IOVE. For the chromophobe and translocation subtypes, there was no significant relationship between 1L therapies and the outcomes. IOIO was associated with the highest ORR and the longest median OS for mnccRCC with sarcomatoid dedifferentiation. Conclusions: Contemporary therapies seem to be effective against mnccRCC, although histology-specific strategies may guide personalized treatment selection. Histologic subtype IOIO IOVE CABO SUN/PAZ mTOR p-value Papillary (n = 54) (n = 31) (n = 25) (n = 499) (n = 116) ORR, n (%) 12/46 (26.1%) 9/29 (31.0%) 7/19 (36.8%) 52/407 (12.8%) 3/87 (3.4%) <0.001 Median OS (95% CI), months 31.9 (20.3–NA) 33.2 (18.6–NA) 30.7 (17.5–48.7) 17.2 (15.3–19.6) 13.1 (11.1–15.4) 0.002 Unclassified (n = 50) (n = 20) (n = 10) (n = 179) (n = 28) ORR, n (%) 14/45 (31.1%) 5/17 (29.4%) 0/7 (0%) 22/149 (14.8%) 1/22 (4.5%) 0.018 Median OS (95% CI), months 18.8 (13.8–29.0) 15.5 (11.1–NA) 7.6 (2.1–NA) 13.6 (11.0–16.7) 6.1 (3.6–9.5) <0.001 mnccRCC with sarcomatoid dedifferentiation (n = 47) (n = 12) (n = 2) (n = 141) (n = 34) ORR, n (%) 16/41 (39.0%) 2/10 (20.0%) 0/2 (0%) 16/106 (15.1%) 1/26 (3.8%) 0.003 Median OS (95% CI), months 31.9 (19.3–NA) 14.0 (2.1–NA) 14.3 (7.6–NA) 12.8 (7.0–13.9) 6.6 (3.6–12.5) <0.001
Impact of federal funding for graduate medical education on residency program size: Evidence from the Affordable Care Act
Primary care and rural physician shortages are a present and growing concern to policy makers. We assessed three Affordable Care Act (ACA) provisions that changed the maximum number of residents teaching hospitals could be reimbursed for, an element of graduate medical education (GME) funding known as the resident cap. The results show that an increase in a hospital’s resident cap of one slot under one of these ACA provisions in 2010 is associated with an increase in residency program size of approximately one full-time equivalent resident. We find important heterogeneity in the magnitude of the association between resident cap changes and program growth across ACA provisions, as well as in whether these associations are driven by changes in primary or non-primary care program growth. These results suggest that targeted changes to GME funding may be an effective tool in helping address physician shortages.
Hemodynamic effects of stenosis with varying severity in different segments of the carotid artery using computational fluid dynamics
External validation of previously reported prognostic classifications for patients treated with second-line axitinib after immuno-oncology combination therapy for advanced renal cell carcinoma: JUOG retrospective study.
482 Background: To validate the prognostic classifications previously reported for patients with advanced renal cell carcinoma who received second-line axitinib after treatment with nivolumab and ipilimumab. Methods: This study included 86 patients from 27 JUOG participating institutions. Treatment outcomes for axitinib as a second-line therapy were collected retrospectively. The prognostic classifications evaluated included the MSKCC risk model (5 factors), IMDC risk model (6 factors), JMRC risk model (4 factors [Cancer Sci. 2012]), ACL risk model (3 factors: albumin, LDH, CRP [Urol Oncol. 2019]), and ATP risk model (4 factors: metastatic disease at diagnosis, number of metastatic sites, albumin level, neutrophil lymphocyte ratio [Cancer Sci. 2020]). An external validation was conducted to evaluate the predictive accuracy for overall survival. Furthermore, risk factors associated with overall survival (OS) were examined using the Cox proportional hazards model. Variables with a p-value less than 0.05 in the univariate analysis were included in the multivariate analysis. Results: The median observation period was 17 months. The median OS and progression-free survival (PFS) for second-line axitinib treatment following immuno-oncology combination therapy were not reached (95% CI: 20-NR) months and 13 (95% CI: 8-14) months, respectively. The best overall response rates were CR 4.7% and PR 34.9%. The integrated Time-Dependent AUC for the MSKCC, IMDC, JMRC, ACL, and ATP classifications were 0.76, 0.76, 0.70, 0.78, and 0.69, respectively. In analyzing treatment prognostic factors, univariate analysis identified significant prognostic factors: less than one year from initial diagnosis, Karnofsky Performance Status <80%, hemoglobin < lower limit of normal, platelet count > upper limit of normal, neutrophil-lymphocyte ratio, albumin level, and CRP level. In the multivariate analysis, only the albumin level was identified as a significant prognostic factor (HR 1.85, 95% CI: 1.18-75.59, p=0.02). Conclusions: Pre-treatment albumin level was an independent prognostic factor for OS of the patients with second line axitinib treatment after immune-oncology combination therapy. Five prognostic models demonstrated comparable accuracy for predicting OS. It is noteworthy that the ACL risk model exhibited a good performance despite its simplicity, comprising only three factors. Comparison of trends in the area under the curve (AUC) values of time-dependent receiver operating characteristic (ROC) curves (prognostic performance) among five prognostic models for OS. Risk model 6 month 12 month 18 month 23 month Integrated ACL 0.77 0.80 0.77 0.74 0.78 IMDC 0.81 0.75 0.68 0.76 0.76 MSKCC 0.80 0.73 0.70 0.72 0.76 JMRC 0.71 0.65 0.67 0.67 0.70 ATP 0.73 0.65 0.68 0.68 0.69
Real-world outcomes in metastatic prostate cancer patients with ctDNA-detected <i>SPOP</i> mutations.
110 Background: Comprehensive genomic profiling (CGP) is recommended for patients (pts) with metastatic prostate cancer (mPC) to inform therapy. ctDNA analysis provides rapid results with high concordance to tissue-based CGP avoiding the need for invasive biopsy. SPOP mutations ( SPOP+ ) define a novel group of mPC enriched in black pts. Tissue-based data suggests a subset of pts with SPOP+ mPC have improved outcomes with hormonal therapy and may not require intensified treatments. This study examined outcomes for mPC pts following ctDNA-detected SPOP mutations by race. Methods: Real-world (rw) data was sourced from GuardantINFORM from 2014 to September 2024. GuardantINFORM is comprised of aggregated commercial payer health claims and de-identified records from pts with clinical ctDNA testing via Guardant360 (G360). Index date was defined as the first metastatic claim post-mPC diagnosis and baseline period as the six months prior to the index date. Adult mPC pts with >2 mPC claims in the baseline period were analyzed. Demographics and rw first-line outcomes (rw time to next treatment (rwTTNT) and rw overall survival (rwOS), months) in both unmatched and propensity score matched and weighted SPOP + vs. SPOP- were assessed. A subgroup analysis was also conducted by stratifying by the two main racial groups, white and black. Results: SPOP mutations were observed in 2.6% of pts meeting inclusion criteria (346/13283). 346 SPOP+ mPC pts were included as cases, of which 205 (59%) were White, 90 (26%) Black, and 51 (15%) other/unknown race; 43% had prior ADT use (n=151) and the median age was 72 years (range: 45-84). A larger proportion of black pts were in the SPOP + cohort compared to SPOP - (21.8% vs. 14.9%) with other demographics similar between cohorts (age, non-Black race, line of therapy, prior ADT use). In unmatched analyses, SPOP+ had numerically similar median rwTTNT and shortened median rwOS compared to SPOP -, although not significant [rwTTNT: SPOP + 12.7 (10.1-14.3) vs. SPOP - 12.4 (11.8-13.0); p=0.86; rwOS: SPOP + 18.3 (15.2-25.8) vs. SPOP - 21.9 (20.7-22.7); p=0.33]. Upon stratifying by race in matched and weighted cohorts, SPOP + black pts had numerically improved median rwTTNT and median rwOS compared to SPOP + white pts, yet not significant [rwTTNT: Black- SPOP + 13.7 (9.2-NR) vs. White- SPOP + 12.4 (8.3-14.5); p=0.66; rwOS: Black- SPOP + 18.9 (14.7-NR) vs. White- SPOP + 17.1 (13.1-29.1); p=0.38]. Conclusions: This data supports ctDNA use for detecting S POP mutation status in mPC. SPOP + may impact rwTTNT and rwOS among black pts. Further modeling of real-world matched cohorts and additional studies in clinical cohorts are needed to continue to assess the impact of SPOP + on patient outcomes.
Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer.
TPS274 Background: Prostate cancer remains the most common malignancy among men and the fifth leading cause of cancer-related mortality globally. Over the past 15 years, advances in imaging techniques and therapeutic options have significantly transformed the management of recurrent, advanced, and metastatic prostate cancer. However, treatment efficacy and toxicity are highly influenced by prior therapy sequences, highlighting the need for a deeper understanding of the optimal treatment sequence. The prospective real-world evidence registry, PROCARE, addresses this gap by documenting treatment patterns, imaging exams, oncologic outcomes, and safety profiles in routine clinical practice. Methods: This study focuses on four distinct patient cohorts: biochemical recurrence after local treatment with curative intent (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof), non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC). PROCARE is a comprehensive long-term follow-up registry designed to document treatment patterns and outcomes in patients receiving systemic treatment. The study aims to enroll 5,000 patients across 50 sites in Germany. Recruitment is being conducted independently for each cohort, beginning with the mHSPC and mCRPC cohorts. First patient in was in January 2024. Patients will remain in the registry from the time of enrollment until death, withdrawal of consent, or study cohort closure. Throughout the study, additional blood samples will be collected at baseline and with each treatment change, respectively, and at first routine follow-up visit thereafter for exploratory research purposes, such as assessing circulating tumor DNA and RNA, as well as genome-wide single nucleotide polymorphisms (SNPs). This approach will enable a deeper understanding of treatment distribution, sequencing, efficacy, and safety in the real-world setting, contributing valuable insights into the evolving therapeutic landscape. Furthermore, analyses from liquid biopsies might provide important insights potentially guiding future therapeutic strategies for recurrent and metastatic prostate cancer. Clinical trial information: DRKS00033411 .
Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).
444 Background: Phase II data from the CALYPSO study (NCT02819596) has shown activity for durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D+S) in MET-driven advanced papillary renal cancer (aPRC), resulting in the ongoing randomised phase III study, SAMETA (NCT03091192). Here we present the final efficacy and new ctDNA analysis. Methods: The aPRC cohort was a single arm study of D+S in both untreated and previously treated disease. Efficacy endpoints include response rates (RR) as per RECIST 1.1, progression-free survival (PFS) and overall survival (OS). PD-L1, TMB and MET status were analysed. Safety was assessed via CTC criteria. FoundationOne CDx was used to profile tissue in 41 patients. Plasma was collected for ctDNA analysis (FoundationOne Tracker analysis; n=21) at baseline (pre-treatment) and sequential time points on treatment. MET mutations were also tracked using F1 Tracker following identification by the F1CDx assay. Results: At 41 months follow-up, the RR in the Intention to Treat (ITT) aPRC population (n=41) was 34% (95% CI, 20-51) and 59% (95% CI, 33-82) in MET-driven patients (n=17). The median PFS was 8.4 months (95% CI, 3.0-13.9) in the ITT population and 16.7 months (95% CI, 5.1-31.4) in MET-driven patients. The median OS was 18.3 months (95% CI, 7.3-30.6) in the ITT population and 27.4 months (95% CI, 9.3-51.6) in MET-driven patients. The hazard ratio (HR) for PFS and OS in MET-driven vs non-MET-driven in PRC cohort was 0.36 (p=0.02) and 0.76 (p=0.43), respectively. 66% of patients were PD-L1+, and 32% were both MET-driven/PD-L1+. The PD-L1 biomarker did not enrich for responders. 27% patients had tissue TMB >median (2.52mut/Mb). TMB was not associated with outcome. 10/16 (63%) were ctDNA positive at baseline, which was associated with a shorter median OS of 7.3 vs 36.4 months (HR 3.91, p=0.02). The mean reduction in Variant Allele Frequency (VAF) was 43% with therapy. For patients with pre- and on-treatment ctDNA, those with CR/PR had ctDNA VAF reduction while those with SD/PD had ctDNA VAF increase (p=0.05). ctDNA clearance was associated with improved PFS (p=0.04). Only 2 patients had MET mutations tracked. ctDNA positivity did not correlate with MET alterations, PD-L1 status or the presence of visceral metastases. Conclusions: D+S continue to show impressive efficacy in MET driven tumors, supporting the ongoing SAMETA trial. ctDNA monitoring on therapy holds promise as a prognostic and potentially predictive tool in this setting. Clinical trial information: NCT02819596 .
Increasing rice yield with low ammonia volatilization by combined application of controlled-release blended fertilizer and densification
Controlled-release blended fertilizer (CRBF) and densification can increase rice yield and nitrogen (N) efficiency. However, the effects of CRBF combined with densification on rice yield, N absorption, economic benefits of fertilization, and ammonia volatilization loss remain unclear. A 2-year field experiment was conducted using five treatments: no N (control, CK), conventional N application (farmer’s fertilization practice, FFP), optimal N application (OPT), single basal application of CRBF (CRBF), and CRBF combined with densification (CRFDP). Moreover, rice yield, N absorption and use efficiency, economic benefit, and ammonia volatilization loss were evaluated. CRBF and CRFDP significantly increased rice dry matter, N use efficiency by 11.6%–30.5% and 90.2%–160.0%, finally increased the yield by 33.3% and 26.1% in 2021 and 2022, respectively. Compared with FFP, CRFDP with 16.7% reduction of N input significantly increased yield by 33.3% and 26.1% and economic benefit by 46.9% and 38.3% in 2021 and 2022, respectively. Compared with CRBF, CRFDP increased the total yield by 2.7% and 15.2%, economic benefit by 3.5% and 7.6%, and N absorption efficiency by 10% and 8.3% in 2021 and 2022, respectively. Compared with FFP, CRFDP reduced ammonia volatilization intensity by 62.5% and 60.8%, cumulative ammonia volatilization loss by 46.3% and 50.3% and also lowered NH4+-N of surface water by 69.0%–93.8% and 57.8%–89.7% in 2021 and 2022, respectively. The combination of CRBF and densification could improve the rice yield, economic benefit, and N use efficiency and reduce ammonia volatilization. These results might provide data and theoretical support for the high yield of rice and a new environmentally friendly and resource-efficient model of rice cultivation.
Nutrition regulates reproductive senescence and terminal investment across the reproductive cycle of a long-lived mammal
Renal cell carcinoma in kidney transplant recipients receiving immunosuppression: A 55-year retrospective single-center study.
599 Background: Immunosuppression, the key post-transplant therapy to prevent organ rejection, is associated with an increased cancer risk. Kidney transplantation is the most frequent solid organ transplant, with renal cell carcinoma (RCC) being the most common urologic cancer in kidney transplant recipients (KTR). While numerous retrospective studies address RCC onset in KTR, they often have limitations, including small sample size, case series design, and lack of annotation regarding pathological features and immunosuppressive regimens adopted. Methods: We retrospectively evaluated 2,571 KTR between 1969 and 2024 at Grande Ospedale Metropolitano Niguarda, Milan, Italy. The primary aim was to assess the incidence of RCC after kidney transplantation. Also, we examined pathological features, including tumor histology, grade, stage, and site (native kidney or graft). Time from transplantation to RCC diagnosis and immunosuppressive regimens were assessed. Overall survival (OS) was evaluated using Kaplan-Meier estimates and Cox proportional hazards model. Results: RCC was diagnosed in 44 KTR, with an incidence of 1.7% (44/2,571, 95%CI 1.2-2.2). Median age at transplant was 48 years (IQR 38-57), with a median time from transplantation to RCC diagnosis of 9 years (IQR 3-18). RCC was diagnosed mostly in males (34/44, 77.3%) and in native kidney (33/44, 75%). Most cases were localized (42/44 pT1-T2, 95.5%), and all received definitive treatment including surgery (41/42, 97.6%) or radiofrequency (1/42, 2.4%). Stage IV at diagnosis was infrequent (2/44, 4.5%). With a median follow-up time of 7 years (IQR 2-10), RCC relapse after definitive treatment was rare (1/42, 2.4%). Bilateral or multiple tumors were observed in 3/44 patients (6.8%), with papillary histology (pRCC) as the most common subtype (24/47, 51.1%). Most KTR received triple immunosuppressive regimens, typically including steroids (90%), calcineurin inhibitors (86.4%), and mycophenolate (75%). There was no significant difference in clinical-pathological characteristics between patients with clear cell carcinoma (ccRCC) or pRCC. Median OS was 28 years (95%CI 23-NR) after transplantation and 10 years (95%CI 8-NR) after RCC diagnosis. Conclusions: This is to our knowledge the largest Italian monocentric case series of RCC arising in KTR. We observed a RCC incidence of 1.7% in this KTR population. The predominance of pRCC in this setting (51%) aligns with findings from previous studies with a higher frequency in KTR compared to the expected proportion in the general population (~10-15%). Despite a generally favorable prognosis, the low incidence of advanced-stage disease at diagnosis underscores the importance of early detection and vigilant surveillance in this high-risk population of KTR.
The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC).
445 Background: The treatment landscape of mRCC has evolved in recent years with the advent of immune-checkpoint inhibitors (ICIs). The Area Deprivation Index (ADI) measures social determinants of health geographically, ranking neighborhoods by socioeconomic disadvantage. However, there are limited data on ICIs outcomes in relation to ADI. We investigated the association between ADI and clinical outcomes of ICI in mRCC. Methods: We conducted a retrospective analysis of 560 mRCC patients (pts) treated at our institution from 2013 to 2024. Eligibility included metastatic disease and ICI treatment at any line. Baseline characteristics and treatment outcomes were obtained from chart review. The ADI scores were calculated by entering the pts addresses at the time of starting ICI into the Neighborhood Atlas. The results were categorized into four quartiles (1st:1-25, 2nd: 26-50, 3rd: 51-75, 4th: 76-100), with higher scores indicating greater deprivation. Overall survival (OS) and progression-free survival (PFS) were calculated from the start of ICI by the Kaplan-Meier method. Immune-related toxicity was assessed across ADI groups. Univariate and multivariate analyses were performed to assess the impact of ADI on survival outcomes, controlling for confounding variables. Results: Our analysis included 287 eligible mRCC pts. Most pts were male (n=208, 72%) with a median age at ICI start of 63 years. Primary histology was clear cell in 238 pts (83%). Pts were 79% White, 13% Black, and 7% other races. Most pts received ICI in the first line (65%) and in combinations (71%). Based on ADI quartiles, 46.3% were in the 1st, 32.4% in the 2nd, 15.3% in the 3rd, and 6% in the 4th quartile. Survival analyses revealed that pts in the highest ADI quartile (4th) had significantly shorter OS (p=0.01) and PFS (p=0.03) compared to those from areas with lower ADI scores. Multivariate analysis confirmed shorter OS in the highest ADI quartile (HR 2.39 [1.32, 4.31], p=0.004). No significant differences in immune-related toxicity rates were observed. Univariate analysis of the continuous ADI values revealed a correlation of higher scores with shorter OS (HR 1.24 [95% CI: 1.06-1.46] p=0.008) and PFS (HR 1.17 [95% CI: 1.02-1.35] p=0.03). Conclusions: Despite landmark improvements in survival outcomes with ICIs in mRCC, pts in deprived areas continue to experience poorer outcomes, highlighting the need for targeted interventions to enhance access to care and to better understand how neighborhood deprivation impacts overall health both prior to diagnosis and over the course of care. Further pan-cancer studies are essential to validate these findings.
Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.
167 Background: Addition of docetaxel (D) to ADT has demonstrated improved overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). In this post hoc OS analysis of the CHAARTED trial (NCT00309985), we report 10-year OS and cause of death (COD) by baseline clinical factors, PSA nadir at 6 months in mHSPC patients treated with ADT +/- D. Methods: An updated survival sweep was conducted in July 2024. Patients were prospectively identified by the state of metastatic disease (metachronous/prior local therapy vs. synchronous/no prior local therapy) and low volume (LV) vs. high volume (HV; visceral and/or ≥4 bone metastases with one lesion beyond the vertebral bodies or pelvis) disease. OS defined as time from 6 mos post randomization to death was calculated using the Kaplan-Meier method and compared between PSA nadir (<0.2 vs. ≥0.2) groups using the log rank test. Results: A total of 334 patients achieved PSA nadir of <0.2 at any timepoint with a median time to PSA nadir of 4.8 months. At 6 months, PSA nadir <0.2 was seen in 204 (26.8%) patients. Patients with PSA nadir <0.2 had significantly better median OS in both ADT + D (100.3 vs. 45.4 mos; P<0.0001; Table) and ADT (116.8 vs. 31.8 mos; P<0.0001) arms. This prognostic impact was significant across prespecified prognostic subgroups. Of the 101 patients who achieved a PSA of < 0.2 at 6 mos, the COD was ‘prostate cancer’ in 58.4% (n=59), ‘other’ in 14.9% with 26.7% being unknown. Of the unknown/missing (n=27), 10 patients died without a record of having progression. In the PSA nadir ≥0.2 group, the reported COD was ‘prostate cancer’ in 78.2% with 6.5% being ‘other' and 15.4% being unknown/missing. Conclusions: Compared with patients with PSA ≥0.2, PSA nadir of <0.2 at 6 months was associated with less prostate cancer deaths and more than doubling of the median OS with approximately 50% of patients alive at 8 years across treatment and all prespecified prognostic groups except de novo high volume treated with ADT alone. Clinical trial information: NCT00309985 . Outcomes by PSA nadir at 6 months in overall population and pre-specified subgroups. ADT+ D ADT # Death/N Median OS (95% CI; months) p-value # Death/N Median OS (95% CI; months) p-value Overall 6-month PSA <0.2 66/127 100.3 (70.4, NA) <0.0001 35/77 116.8 (87.3, 141.5) <0.0001 6-month PSA ≥0.2 203/256 45.4 (39.2, 51.6) 246/301 31.8 (26.3, 38.1) Denovo HV6-month PSA <0.2 20/39 93.5 (45.9, NA) 0.0001 7/11 74.7 (37.4, NA) 0.007 6-month PSA ≥0.2 135/166 39.5 (32.8, 48.5) 162/183 26.4 (23.5, 32.0) Metach HV6-month PSA <0.2 12/23 105.7 (61.4, NA) 0.0009 8/15 87.3 (47.4, NA) 0.0002 6-month PSA ≥0.2 22/25 43.2 (23.5, 66.0) 25/26 22.1 (13.9, 39.4) Metach LV6-month PSA <0.2 18/34 101.5 (58.6, NA) 0.04 11/38 123.4 (123.4,141.5) 0.003 6-month PSA ≥0.2 17/21 63.6 (49.7, 99.3) 14/26 48.9 (25.6, NA)
Characterization of genitourinary drug approvals by the FDA, 2020-2024.
872 Background: There were 255 cancer drug approvals by the US Food and Drug Administration (FDA) between January 2020 and October 2024. Although genitourinary (GU) cancers (prostate, urothelial, renal and testicular) compromise some of the most prevalent malignancies, it is unclear how many of these drug approvals were intended for treatment of genitourinary cancers. Methods: Using the list of FDA cancer drug approvals, we identified approvals for GU cancer indications between January 2020 and October 2024. We collected data on tumor type, line of treatment, control arm, primary endpoint(s) as studied in the corresponding clinical trial, and phase of clinical trial. Results: We identified a total of total of 26 drug approvals for GU cancer indications (10.2%) among the total 255 drug approvals for all cancer types. Among these approvals, 12 were for urothelial, 9 for prostate, and 5 for renal. There was variation in the line of setting for each approval’s intended use as shown in the table. No cancer drug approvals were for testicular, penile or adrenal cancer. Most trials were phase III (n = 20), followed by phase II (n = 4) and then one each for phase IB/II and II/III. Overall survival was the most common endpoint (n = 10), followed by response rate and duration of response (n = 7), radiographic progression-free survival (n = 5), disease-free survival (n = 2), and one each for castration rate and metastasis-free survival. Conclusions: Drug approvals for GU cancers compromised approximately 10% of drug approvals by the FDA over the past five years. While OS continues to be the most commonly used endpoint in clinical trials, response rate and duration of response are commonly employed in BCG-refractory non-muscle invasive bladder cancer trials and radiographic progression-free survival in prostate cancer trials. Given the high incidence and mortality from GU cancers, continued drug development is warranted. Intended setting of use for genitourinary cancer drug approvals by tumor type, 2020-2024. Tumor Type Number Indication Urothelial 12 First line (n = 3), adjuvant (n = 1), maintenance (n = 1), BCG-refractory/UTUC (n = 4), second- or later-line (n = 3) Prostate 9 Hormone-sensitive (n = 2), hormone-resistant (n = 1), biochemical recurrence (n = 1), BRCA/HRD mutated (n =5) Renal 5 First-line (n = 2), adjuvant (n = 1), second- or later-line (n = 2) Testicular 0 No applicable Penile 0 Not applicable Adrenal 0 Not applicable 26
Modelling the impact of behavioural interventions during pandemics: A systematic review
Background Many studies examined the impact of behavioural interventions on COVID-19 outcomes. We conducted a systematic review to gain insight into transmission models, following PRISMA 2020 guidelines. We included peer-reviewed studies published in English until December 31, 2022, focusing on human subjects, modelling, and examining behavioural interventions during COVID-19 using real data across diverse geographical regions. Methods We searched seven databases. We used descriptive analysis, network analysis for textual synthesis, and regression analysis to identify the relationship between the basic reproduction number R 0 and various characteristics. From 30, 114 articles gathered, 15, 781 met the inclusion criteria. After deduplication, 7, 616 articles remained. The titles and abstracts screening reduced these to 1, 764 articles. Full-text screening reduced this to 270, and risk-of-bias assessment narrowed it to 245 articles. We employed combined criteria for risk of bias assessment, incorporating domains from ROBINS-I and principles for modeling. Results Primary outcomes focused on R 0 , COVID-19 cases, and transmission rates. The average R 0 was 3.184. The vast majority of studies (90.3%) used compartmental models, particularly SEIR models. Social distancing, mask-wearing, and lockdowns were frequently analyzed interventions. Early and strict implementation of these interventions significantly reduced transmission rates. Risk of bias assessment revealed that 62.6% of studies were of low risk, 24.1% moderate, and 9.3% high risks. Common issues included transparency, attrition bias, and confounding factors. Conclusions This comprehensive review highlights the importance of behavioural interventions in reducing COVID-19 transmission and areas for improving future research transparency and robustness. Our risk of bias criteria offers an important framework for future systematic reviews in modeling studies of interventions. We recommend that future studies enhance transparency in reporting and address common biases such as attrition and confounding.